Retatrutide

Retatrutide: Complete Guide to the GIP/GLP-1/Glucagon Triple Agonist

Advances in metabolic research have led to the development of multi-receptor agonists that target several pathways involved in appetite regulation, energy balance, and glucose metabolism. Earlier incretin-based therapies focused mainly on GLP-1 receptor agonism, while newer investigational compounds expand this approach to dual- and triple-receptor activity. Within this landscape, Retatrutide, also known as LY3437943, has emerged as an investigational peptide from Eli Lilly designed to activate GLP-1, GIP, and glucagon receptors simultaneously. This triple-agonist profile distinguishes Retatrutide from earlier agents by combining appetite-related signaling, incretin activity, and glucagon-mediated metabolic effects in a single molecule. It is being studied as a once-weekly subcutaneous injection and remains in clinical development, not yet in commercial use. This content is for informational purposes only and does not constitute medical advice.

What Is Retatrutide?

Retatrutide is an investigational triple hormone receptor agonist that targets glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon receptors. Eli Lilly developed it and is commonly referenced by its development code, LY3437943. The compound is being studied primarily for obesity and related cardiometabolic conditions because its mechanism is intended to influence appetite, body weight, glycemic regulation, and energy expenditure through multiple pathways. As of 2026, it is not FDA-approved for routine prescribing or commercial sale. Within the broader peptides category, Retatrutide stands out as a next-generation investigational compound.

Retatrutide Mechanism of Action

The mechanism of the Retatrutide peptide is based on simultaneous agonism of three receptor systems: GLP-1, GIP, and glucagon. This multi-pathway design is the main reason it has drawn attention in obesity research, since each receptor contributes differently to metabolic regulation. By combining these receptor activities, Retatrutide is being evaluated as a multi-pathway metabolic peptide in clinical research. Rather than focusing solely on satiety or glucose response, its mechanism enables investigation of broader endocrine and energy-balance systems, including food intake, insulin signaling, fat metabolism, and hepatic activity.

GLP-1 Receptor Agonism

GLP-1 receptor activity is associated with appetite suppression, increased satiety, delayed gastric emptying, and improved postprandial glucose handling. This pathway forms the backbone of several established obesity and diabetes therapies. For a GLP-1-only comparator, see the Semaglutide guide, while the Tirzepatide guide provides context on dual GIP/GLP-1 incretin signaling that Retatrutide expands on through added glucagon receptor agonism.

GIP Receptor Agonism

GIP receptor agonism may support insulin secretion in response to nutrient intake and may also affect adipose and lipid-related signaling. In multi-agonist therapies, this pathway is often discussed as a complementary incretin mechanism rather than a stand-alone driver of weight loss.

Glucagon Receptor Agonism

Glucagon receptor agonism helps differentiate Retatrutide from GLP-1-only and GLP-1/GIP agents because it is being studied for its potential role in energy expenditure and hepatic fat metabolism. This added pathway is one reason Retatrutide is often described as a next-generation metabolic peptide under investigation. Together, these three receptor pathways create a broader metabolic profile than single- or dual-agonist compounds. In research settings, this combination is being evaluated for its potential to influence food intake, glucose control, weight loss, lipid markers, and liver-related outcomes within a single treatment model.

Retatrutide Clinical Trial Results

The most widely cited obesity data come from the Phase 2 trial published in The New England Journal of Medicine in 2023, which reported a mean weight reduction of up to 24.2 percent at 48 weeks in the highest-dose group. The study showed a dose-dependent response, with higher weekly doses producing greater average weight loss. Phase 2 findings also showed improvements in several cardiometabolic measures, supporting continued interest in the compound beyond body weight alone. These early results helped position Retatrutide as one of the most closely watched obesity drugs in development, but they do not replace the need for confirmatory late-stage data. Retatrutide has since advanced into the Phase 3 TRIUMPH clinical program, where it is being studied across obesity and related conditions. Because those studies are part of an ongoing development program, any article describing the compound should make clear that long-term efficacy, safety, and eventual regulatory outcomes are still being evaluated.

Retatrutide Dosage Clinical Reference

Retatrutide is being studied as a once-weekly subcutaneous injection in clinical trials. In Phase 2 obesity research, dose levels included 1 mg, 4 mg, 8 mg, and 12 mg weekly, with the 12 mg dose associated with the greatest weight reduction in the published trial. For a related peptide discussion that also involves titration and tolerability, see the Cagrilintide guide. Dose escalation is an important part of the investigational regimen because gastrointestinal adverse effects are more common during titration with incretin-based therapies. Since Retatrutide is not commercially approved, these dosing schedules should be described as clinical trial protocols rather than standard prescribing guidance.

Retatrutide Benefits

Retatrutide is being studied for its potential to simultaneously affect multiple aspects of metabolic regulation, including body weight, glycemic measures, lipid-related markers, and liver-associated outcomes. Its triple-agonist design is why it is often discussed as a broader metabolic therapy candidate rather than merely an appetite-focused peptide. Potential areas of interest in the current research include:

• Substantial weight-loss efficacy in obesity trials, with the strongest published Phase 2 result reaching 24.2 percent at 48 weeks.
• Multi-pathway metabolic effects involving appetite signaling, incretin response, and glucagon-mediated energy pathways.
• Once-weekly dosing, which aligns with the administration model used by other long-acting incretin therapies.
• Ongoing evaluation of broader cardiometabolic effects, including glucose, lipid, and liver-related measures.

These benefits remain investigational and should not be presented as established clinical outcomes outside the trial setting.

Retatrutide Side Effects

Reported adverse effects are broadly consistent with those seen in incretin-based therapy development, particularly gastrointestinal symptoms such as nausea, vomiting, diarrhea, constipation, and abdominal discomfort. These effects are often more noticeable during early dose escalation. Other tolerability considerations under evaluation include increased heart rate, injection-site reactions, and gallbladder-related events such as cholelithiasis. As with efficacy, the long-term safety profile of Retatrutide depends on the results of ongoing larger trials.

Retatrutide vs Tirzepatide vs Semaglutide vs Mazdutide

Retatrutide is frequently compared with other incretin-based agents because each compound targets a different receptor combination. The most important distinction is that Retatrutide adds glucagon receptor agonism to the GLP-1 and GIP pathways, while tirzepatide targets GLP-1 and GIP, semaglutide primarily targets GLP-1, and mazdutide combines GLP-1 with glucagon activity. For the closest mechanistic comparison, see the Mazdutide guide, as Mazdutide shares the glucagon component but lacks GIP receptor agonism.

Compound	Targets	Max weight loss reported	Approval status	Dosing	Manufacturer
Retatrutide	GLP-1, GIP, glucagon	24.2% in the Phase 2 obesity trial at 48 weeks	Not approved; in clinical development	Weekly	Eli Lilly
Tirzepatide	GLP-1, GIP	Approved product data differ by indication and trial; do not compare directly with Retatrutide Phase 2 data without context	Approved in multiple markets	Weekly	Eli Lilly
Semaglutide	GLP-1	Approved product data differ by indication and trial; comparisons require context	Approved in multiple markets	Weekly	Novo Nordisk
Mazdutide	GLP-1, glucagon	Clinical data continue to emerge	In clinical development in some markets	Weekly	Innovent and partners

In practice, Retatrutide should be framed as an investigational next-generation candidate rather than as a proven replacement for approved therapies. Cross-trial comparisons can be useful for context, but they should be presented cautiously because study populations, endpoints, durations, and dose regimens differ.

FAQs

1. How much weight loss does Retatrutide cause?

In the published Phase 2 obesity study, the highest-dose group achieved a mean weight reduction of up to 24.2 percent at 48 weeks. That figure is one of the strongest published results to date for an obesity drug in clinical development. However, it comes from a Phase 2 trial and still requires confirmation through later-stage studies.

2. Is Retatrutide approved?

No. Retatrutide is not FDA-approved for routine commercial use and remains in clinical development. Any current access claims should be treated with caution unless tied to legitimate research participation or to future regulatory action.

3. How does Retatrutide differ from Tirzepatide?

Tirzepatide targets GLP-1 and GIP receptors, while Retatrutide adds a third mechanism through glucagon receptor agonism. That extra pathway is being studied for its possible contribution to energy expenditure and liver-related metabolic effects.

4. When will Retatrutide be available?

Availability depends on completion of ongoing clinical development, regulatory review, and final approval decisions.

References

1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Triple-hormone-receptor agonist retatrutide for obesity. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972.
2. gov. A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight (TRIUMPH-1). NCT05929066. Accessed May 21, 2026. https://clinicaltrials.gov/study/NCT05929066
3. gov. A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity (TRIUMPH-5). NCT06662383. Accessed May 21, 2026. https://clinicaltrials.gov/study/NCT06662383
4. Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. Retatrutide-A Game Changer in Obesity Pharmacotherapy. Biomolecules. 2025;15(6):796. Published 2025 May 30. doi:10.3390/biom15060796
5. Abdul-Rahman T, Roy P, Ahmed FK, et al. The power of three: Retatrutide's role in modern obesity and diabetes therapy. Eur J Pharmacol. 2024;985:177095. doi:10.1016/j.ejphar.2024.177095

Disclaimer

For licensed medical professionals only. This content is for informational purposes only and does not constitute medical advice.